Insilico Medicine Cayman TopCo (Insilico) and its wholly owned subsidiary Insilico Medicine Hong Kong Limited disclosed three new treasury allocations on 29 April 2026, involving a total principal of USD105.00 million. All commitments were funded from internal resources and are classified as discloseable transactions under Hong Kong Listing Rule 14.22.
• USD50.00 million was committed by the parent company to the CMB International USD Money Market Fund managed by CMB International Asset Management. The non-guaranteed product targets an indicative annualised return of 3.99 % and is redeemable on any business day.
• Insilico Hong Kong subscribed USD50.00 million to JPMorgan Asset Management’s USD Standard Money Market VNAV Fund. Together with a prior USD2.00 million placement on 14 April 2026, the subsidiary’s aggregate holding in this fund totals USD52.00 million. The fund offers an indicative annualised yield of 3.85 % and daily liquidity.
• Insilico Hong Kong also entered a USD/Offshore RMB dual-currency structured deposit with JPMorgan Chase Bank, N.A., Hong Kong Branch, for USD5.00 million. The product carries a fixed 4.68 % annual interest rate and matures on 18 June 2026. Final settlement will be in RMB or USD depending on whether the USD/CNH rate at maturity meets the strike level of CNH6.8350 per USD1.00.
Following these placements, Insilico’s combined bank balances, cash, and financial assets at fair value through profit or loss increased from USD447.00 million at 31 December 2025 to approximately USD596.00 million. Management attributes the USD149.00 million rise chiefly to cash inflows from pipeline development upfront payments, milestone receipts, and software subscription fees.
The Board stated that the surplus funds were not immediately required for operations and that the low-risk, highly liquid products align with the group’s treasury objectives of capital preservation and yield enhancement. Because each individual transaction’s percentage ratio exceeded 5 % but remained below 25 %, shareholder approval was not required, though reporting and announcement obligations under Chapter 14 of the Listing Rules were triggered.